All News
RheumNow Podcast – When You’re Hot You’re Hot (10.11.19)
Dr. Jack Cush delivers select commentary on select news and journal articles from the past week on RheumNow.com.
Read Article
RheumNow Podcast – Women Take Over Rheumatology (10.4.19)
Dr. Jack Cush reviews the News and Journal Reports from this week on RheumNow.com.
Read Article
RheumNow Podcast – Cancer Risk in Systemic Sclerosis (9.27.19)
Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com.
Read Article
Checkpoint Inhibitors: Who Gets Myocarditis?
The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.
Read Article
With Autoimmunity, Checkpoint Inhibitors Can Be Used
Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.
Read Article
RheumNow Podcast – Don’t Take My Advice (7.19.19)
Dr. Jack Cush reports the news and new journal articles from the past week on RheumNow.com.
Read Article
Understanding Non-arthritic Rheumatic iRAEs
A better understanding of rheumatic immune-related adverse event phenotypes beyond inflammatory arthritis has been furthered by work from three abstracts presented at EULAR 2019 in Madrid.
Read Article
RheumNow Podcast – A Tofa Two-fer (4.12.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read Article
Best of 2019 - Ups and Downs with Abatacept
Two recent studies have examined the effect of starting abatacept upon the risk of serious hospitalized infections or cancer, showing divergent results from claims data analyses.
Read Article
RheumNow Podcast – Rheumatologist Salaries (12.21.18)
Dr. Jack Cush reviews the news from RheumNow for the week ending 12/21/18.
Read Article
TIF1-Ab in Dermatomyositis Linked to Higher Cancer Risk
Several epidemiological studies have reported that a diagnosis of DM or PM may be associated with increased cancer risk. The association appears stronger for DM than PM.
Read Article
SLE and Risk of Malignancy
The risk for cancer in systemic lupus erythematosus (SLE) patients has been inconsistently studied. A new metanalysis shows that SLE has an increased risk for 16 specific cancers and decreased risk for prostate cancer and cutaneous melanoma.
Read Article
RheumNow Podcast – Can RA Be Prevented (12.7.18)
Dr. Jack Cush reviews the news and new journal articles from the past week on RheumNow.com:
Read Article
RheumNow Weekly Podcast – 3 Wiseguy Rheumatologists (11.9.18)
Dr Jack Cush reviews the News and Journal reports from the past week on RheumNow.com. Be sure to check out our upcoming meeting in March 2019 - RheumNow Live.
Read Article
Update on Immune Checkpoint Inhibitor Toxicity
JAMA has a 2018 update/review of the safety issues seen with mmune checkpoint inhibitors (ICIs) - important new cancer therapies, with 14 cancer indications, that have significantly improved survival in several. ICIs are monoclonal antibodies that block inhibitors of T-cell activation and function.
Read Article
Quarterly Canakinumab Reduces Gout Risk Without Affecting Uric Acid
The Annals of Internal Medicine reports that interleukin-1 (IL-1) inhibitor treatment is associated with a reduced risk of gout attacks - such are the findings of an anlysis of the CANTOS study previously reported at the Annual ACR 2017 meeting in Washington, DC.
Read Article
No Cancer Risk from Psoriatic Arthritis
Inflammmation is a strong risk factor for malignancy. Yet there are mixed results on whether patients with psoriatic arthritis (PsAg) augments the incidence of cancer and all-cause and cause-mortality.
Read Article
The RheumNow Week in Review – We’re Number One! (8.17.18)
Dr. Cush reviews the articles and news from the last week on RheumNow.com. Information on comorbidities, the downside of steroids, unmet need in psoriatic arthritis, and the top 10 rheumatology programs.
Read Article
Tumor Necrosis Factor Inhibitors Do Not Increase the Risk of Cancer Recurrence
There is a large body of data that shows tumor necrosis factor inhibitors (TNFi) use in rheumatoid arthritis (RA) confers the same risk as that seen in RA - meaning there is no increase over and above that incurred by inflammation and RA itself. There are fewer studies about whether it is s
Read Article
TNF Inhibitors Don't Increase Cancer Risk in Children
While the risk of neoplasia with tumour necrosis factor inhibitor (TNFi) use has been largely nullified in most inflammatory disorders, this risk in children is less certain. However a recent study shows no risk of increased cancer in children treated with TNFi for juvenile idiopathic arthritis (JIA), pediatric inflammatory bowel disease (pIBD) and pediatric plaque psoriasis (pPsO).
Read Article
